Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02200133 · ClinicalTrials.gov registry record · NA
Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors
A NA study, sponsored by Center for International Blood and Marrow Transplant Research.
- Completed
- Registry status
- NA
- Development phase
- 495
- Enrollment target
NCT02200133: Completed NA study, sponsored by Center for International Blood and Marrow Transplant Research.
NCT02200133 is a NA study that has completed, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 495 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02200133, a NA study, has completed, sponsored by Center for International Blood and Marrow Transplant Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 495 participants
- Enrollment target
Study Summary
This randomized study will compare a personalized Survivorship Care Plan (SCP) template with usual care (no SCP). The investigators hypothesize that the personalized SCP that incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications will enhance patient survivorship confidence in knowledge, increase adherence to recommended healthcare, improve health behaviors and reduce HCT-related emotional distress.
Interventions
- OTHER Individualized Survivorship Care Plan (SCP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-04 |
| Phase | NA |
What the finished NCT02200133 record still lists
NCT02200133 is an interventional study that assigns participants to a tested intervention. The registered 495 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which Individualized Survivorship Care Plan (SCP) is the first listed.
NCT02200133 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02200133 about?
NCT02200133 is a clinical study titled "Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors". This randomized study will compare a personalized Survivorship Care Plan (SCP) template with usual care (no SCP). The investigators hypothesize that the personalized SCP that incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures an...
What is the current status of trial NCT02200133?
This trial is currently completed. It is a NA study. The enrollment target is 495 participants. The study started on 2015-04. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02200133?
The interventions under investigation include: Individualized Survivorship Care Plan (SCP) (OTHER).
Who is sponsoring clinical trial NCT02200133?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02200133's enrollment target sits among peer trials
495 213th of 2000 higher than 1,788 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia